Can We Manage Without Biopsy in Membranous Nephropathy With Positive anti-PLA2R Antibodies?
EstadísticasView Usage Statistics
Full recordShow full item record
AuthorRuiz-Martínez, L.; De-Cos-Gómez, M.; Valero-San-Cecilio, R.; Rodrigo Calabia, Emilio; Heras-Vicario, M.; Serrano-Soto, M.; Belmar-Vega, L.; Palomar-Fontanet, R.; Miñambres García, Eduardo; Ruiz San Millán, Juan Carlos
Introduction. Our study compares 2 immunosuppressive strategies to reduce tacrolimus nephrotoxicity and its risk of acute tubular necrosis: delayed introduction of tacrolimus plus thymoglobulin vs initial tacrolimus plus basiliximab on the results of kidney transplant (KT) using type-III donation after circulatory death (III-DCD). Material and methods. We analyzed all the transplants performed using type-III DCD in our hospital (42 cases). They were distributed in a first stage with delayed tacrolimus (3 -4 day) þ thymoglobulin and a second one with initial tacrolimus þ basiliximab, with a followup of 6 months. The rate of delayed graft function, the evolution of renal function, and the incidence of rejection were compared. Results. 28 patients received thymoglobulin with delayed tacrolimus, and 13 patients received basiliximab and tacrolimus from day 0 (1 excluded). There were no significant differences in delayed graft function (27% group 1 and 23% group 2) or in rejection (10.7% and 15.4%), respectively. Serum creatinine at day 3, 7, 14, 30, and 180 showed no statistically significant differences. The levels of tacrolimus measured at 10, 30, 90, and 180 days after transplantation were similar, except for the first month: 10.10 2.3 in group 1 and 12 1.7 ng/mL in group 2 (P ¼ .007). Conclusions. Delayed introduction of tacrolimus does not seem to suppose a benefit in KT using type-III DCD; therefore, the use of thymoglobulin, with its higher
Enlace a la publicación
Collections to which it belong
- D22 Artículos